A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans.
A virosome vaccine delivery system comprised of the hemagglutinin of influenza A virus incorporated into unilamellar liposomes consisting of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) or only PC was developed. The anti-PE and anti-PC antibody response was determined for human volunteers immunized with a virosome-formulated vaccine against hepatitis A, or a standard or virosome-formulated influenza vaccine. None of the 100 young adults who received two doses of the hepatitis A vaccine 1 year apart mounted a significant (greater than fourfold) antiphospholipid antibody response. Immunization with a single dose of trivalent influenza vaccine engendered a significant anti-PC and anti-PE antibody response in 1 of 32 elderly nursing home residents who received the virosome-formulated influenza vaccine and in 1 of the 31 residents who received a commercial subunit vaccine. These findings indicate that the virosome system can potentiate the human immune response to vaccine antigens without a concomitant rise in antiphospholipid antibodies.
Cryz
S J
SJ
Swiss Serum and Vaccine Institute, Berne, Switzerland.
Que
J U
JU
Glück
R
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000096:biosynthesis*; D000914:Antibodies, Viral / Q000097:blood; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D022362:Hepatitis A Vaccines; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D017152:Antibodies, Antiphospholipid; D000914:Antibodies, Viral; D004337:Drug Carriers; D022362:Hepatitis A Vaccines; D014761:Viral Hepatitis Vaccines